IMV Inc. is a clinical-stage immuno-oncology company that specializes in developing therapies to treat solid and hematological cancers. Their DPX technology platform is the basis for their portfolio of therapies, including their lead drug candidate, maveropepimut-S, which is in Phase II clinical trials for various cancers. The company also develops DPX-SurMAGE for bladder cancer and DPX-COVID-19 and DPX-RSV for infectious diseases.